Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...
The Food and Drug Administration is about to decide whether a scientific word can become a regulatory loophole. On July 23 ...
Marshall Hargrave is a stock analyst and writer with 10+ years of experience covering stocks and markets, as well as analyzing and valuing companies. Thomas J. Brock is a CFA and CPA with more than 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results